An antifibrotic compound that ameliorates hyperglycaemia and fat accumulation in cell and HFD mouse models
Diabetologia · 2024-11 · 67 (11) · 2568-2584
DOI: 10.1007/s00125-024-06260-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetologia, online erschienen am 09.09.2024. Verfasst von Tsugumasa Toma und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: Diet, High-Fat, Hyperglycemia, AMP-Activated Protein Kinases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, Kyushu University.
Abstract (Originalsprache)
AIMS/HYPOTHESIS: Appropriate management of blood glucose levels and the prevention of complications are important in the treatment of diabetes. We have previously reported on a compound named HPH-15 that is not only antifibrotic but also AMP-activated protein kinase (AMPK)-activating. In this study, we evaluated whether HPH-15 is useful as a therapeutic medication for diabetes. METHODS: We examined the effects of HPH-15 on AMPK activation, glucose uptake, fat accumulation and lactic acid production in L6-GLUT4, HepG2 and 3T3-L1 cells, as a model of muscle, liver and fat tissue, respectively. Additionally, we investigated the glucose-lowering, fat-accumulation-suppressing, antifibrotic and AMPK-activating effect of HPH-15 in mice fed a high-fat diet (HFD). RESULTS: HPH-15 at a concentration of 10 µmol/l increased AMPK activation, glucose uptake and membrane translocation of GLUT4 in each cell model to the same extent as metformin at 2 mmol/l. The production of lactic acid (which causes lactic acidosis) in HPH-15-treated cells was equal to or less than that observed in metformin-treated cells. In HFD-fed mice, HPH-15 lowered blood glucose from 11.1±0.3 mmol/l to 8.2±0.4 mmol/l (10 mg/kg) and 7.9±0.4 mmol/l (100 mg/kg) and improved insulin resistance. The HPH-15 (10 mg/kg) group showed the same level of AMPK activation as the metformin (300 mg/kg) group in all organs. The HPH-15-treated HFD-fed mice also showed suppression of fat accumulation and fibrosis in the liver and fat tissue; these effects were more significant than those obtained with metformin. Mice treated with high doses of HPH-15 also exhibited a 44% reduction in subcutaneous fat. CONCLUSIONS/INTERPRETATION: HPH-15 activated AMPK at lower concentrations than metformin in vitro and in vivo and improved blood glucose levels and insulin resistance in vivo. In addition, HPH-15 was more effective than metformin at ameliorating fatty liver and adipocyte hypertrophy in HFD-fed mice. HPH-15 could be effective in preventing fatty liver, a common complication in diabetic individuals. Additionally, in contrast to metformin, high doses of HPH-15 reduced subcutaneous fat in HFD-fed mice. Presumably, HPH-15 has a stronger inhibitory effect on fat accumulation and fibrosis than metformin, accounting for the reduction of subcutaneous fat. Therefore, HPH-15 is potentially a glucose-lowering medication that can lower blood glucose, inhibit fat accumulation and ameliorate liver fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt.
- Todaka Internal Medical Clinic, Kumamoto, Japan.
- Research and Development, Science Farm Ltd, Kumamoto, Japan.
- Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. earaki@gpo.kumamoto-u.ac.jp.
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- Kyushu University
- Higo Bank
Zitieren
APA
Toma, T., Miyakawa, N., Arakaki, Y., Watanabe, T., Nakahara, R., Ali, T. F. S., Biswas, T., Todaka, M., Kondo, T., Fujita, M., Otsuka, M., Araki, E., & Tateishi, H. (2024). An antifibrotic compound that ameliorates hyperglycaemia and fat accumulation in cell and HFD mouse models. Diabetologia, 67(11), 2568-2584. https://doi.org/10.1007/s00125-024-06260-y
Vancouver
Toma T, Miyakawa N, Arakaki Y, Watanabe T, Nakahara R, Ali TFS, et al. An antifibrotic compound that ameliorates hyperglycaemia and fat accumulation in cell and HFD mouse models. Diabetologia. 2024;67(11):2568-2584. doi:10.1007/s00125-024-06260-y
BibTeX
@article{Toma2024,
author = {Toma, Tsugumasa and Miyakawa, Nobukazu and Arakaki, Yuiichi and Watanabe, Takuro and Nakahara, Ryosei and Ali, Taha F S and Biswas, Tanima and Todaka, Mikio and Kondo, Tatsuya and Fujita, Mikako and Otsuka, Masami and Araki, Eiichi and Tateishi, Hiroshi},
title = {An antifibrotic compound that ameliorates hyperglycaemia and fat accumulation in cell and HFD mouse models},
journal = {Diabetologia},
year = {2024},
volume = {67},
number = {11},
pages = {2568--2584},
doi = {10.1007/s00125-024-06260-y}
}
EUVIMED